// App-Quantinova.ai

e15208 : Targeting mTOR and VEGF in CRPC: Preliminary results of a phase I/II trial of temsirolimus (T) and bevacizumab (B) in docetaxel-refractory metastatic CRPC.

Researchers

Presenter

  • Jorge A. Garcia

Principal Investigators

  • Paul Elson

  • Matthew M. Cooney

  • Allison Janine Tyler

  • Robert Dreicer

Medical Centers

  • University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH

  • Cleveland Clinic Foundation-Department of Translational Hematology and Oncology Research, Cleveland, OH

  • Cleveland Clinic, Cleveland, OH

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Metastatic castration-resistant prostate cancer

Biomarkers

  • Circulating tumor cells

  • Serine/threonine-protein kinase mTOR

  • Vascular endothelial growth factor A

  • Type 1 T helper

Drug/Treatment

  • Temsirolimus

  • Bevacizumab

  • Docetaxel

Outcome

  • N/A

Study Design

  • N/A

Phase

  • I/II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved